ArticleBJU international2026
Pre-clinical evaluation of a laser system with emission control based on stone vs soft tissue recognition.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Smart Lithotripsy: Lasers, Energy Sources and Efficiency.Current urology reports · 2026Review
- Precision by recognition: smarter firing for better lithotripsy.BJU international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo evaluate the feasibility and performance of the StoneSense™ module (SSM; IPG Medical, Marlborough, MA, USA), a prototype real-time target recognition unit integrated into a IPG Thulium Fiber Laser (TFL). MATERIALS AND
methodsThe SSM analyses the spectral signature of back reflected light-emitting diode (LED) light from the target, stopping laser energy emission when incoming signal is originating from tissue or when the fibre-to-target distance is larger than pre-defined threshold (typically, ≥2-4 mm). The ex vivo tests were conducted on artificial BegoStone phantoms ((Bego GmbH & Co. KG, Bremen, Germany) embedded in porcine kidney tissue using energy settings of 0.1-2 J and 5-100 Hz at two fibre-scanning speeds (1 and 3 mm/s) through a translation stage movement. Human urinary stones were subsequently tested at 2 and 5 mm/s with setting of 0.5 J × 20 Hz. The in vivo trial was conducted by lithotripsy of pre-implanted human stones in porcine urinary tract. Primary outcome measures included ablation efficiency as well as specificity and sensitivity of stone recognition.
resultsSoft tissue ablation was completely prevented in all the ex vivo trials while maintaining high lithotripsy efficiency. Mean stone ablation reduction was 2.75% and 3% at fibre scanning speeds of 1 and 3 mm/s, respectively. The system achieved 100% sensitivity and up to 98% specificity in inhibiting laser emission to soft tissue. In vivo, complete dusting with fragments <500 μm was achieved for all studied stone types without observable mucosal injury. Specificity ranged from 85% to 100%, while sensitivity ranged from 90% to 100%.
conclusionsIntegration of back reflected-light-spectra-based laser emission control into a TFL-based lithotripsy system is feasible and effective. The SSM enables precise real-time stone recognition, minimises unnecessary lasing, and preserves dusting efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.